Technology evaluation: bevacizumab, Genentech/Roche.
Bevacizumab, an antivascular endothelial growth factor monoclonal antibody, is being developed by Genentech and Roche as an anti-angiogenesis therapy for the potential treatment of solid tumors. In June 2003, bevacizumab was granted Fast Track status by the FDA for the potential treatment of first-line colorectal cancer. The antibody is currently in phase III trials for non-small-cell lung, colorectal and breast cancers, and in phase II trials for various other solid tumor types.
Salgaller
Michael L
ML
Toucan Capital Corp, 7600 Wisconsin Ave, 7th Floor, Bethesda, MD 20814, USA. msalgaller@toucancapital.com
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use*; D000068258:Bevacizumab; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051379:Mice; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab